1. Boehringer Ingelheim Pharmaceuticals20112016-04-22Surveys reveal wide gaps in knowledge of genetic mutation testing exist between oncologists, nurses and cancer patients http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2011/november_16_2011.html
2. Boehringer Ingelheim Pharmaceuticals201305072016-04-22Surveys reveal opportunity for medical community to fully embrace biomarker testing in lung cancer http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2013/05-07-13-surveys-medical-community-biomarker-testing-lung-cancer.html
3. Boehringer Ingelheim Pharmaceuticals20152016-04-22New international survey of lung cancer oncologists highlights underutilization of personalized treatments http://newscentre.boehringer-ingelheim.com/diru/news_releases/press_releases/2015/17_april_2015_oncology.html
4. SpicerJTischerBPetersMEGFR mutation testing and oncologist treatment choice in advanced NSCLC: global trends and differencesAnn Oncol2015European Lung Cancer Conference (ELCC)Apr 11-15, 2015Geneva, SwitzerlandAnnals of Oncologyi60
5. UpToDate20162016-03-31http://www.uptodate.com/contents/search